ASBrS Dinner Symposium
Optimizing Molecular Residual Disease (MRD) Testing, Clinical Utility and Workflow in a Multidisciplinary Setting
Date: Wednesday, April 29, 2026
Time: 5:00 – 6:30 PM PT
Room: 609
Address: 705 Pike Street, Seattle, WA
Join us as we examine the breast surgeon’s role in initiating tumor-informed molecular residual disease (MRD) testing at diagnosis. Through focused patient cases, the faculty panel will discuss how detecting circulating tumor DNA establishes a personalized molecular baseline, enables objective assessment of treatment response beyond pCR versus non-pCR, and supports systemic monitoring for recurrence beyond what breast imaging alone can provide.
Attendees will leave with a clear framework for integrating MRD into modern breast surgical practice and an understanding of how early surgical leadership elevates tumor board discussions and advances state-of-the-art, biology-driven breast cancer care.
We look forward to seeing you!
Hear from our Speakers:
Barry S. Rosen, MD, FACS
Dr. Rosen is a nationally recognized breast surgical oncologist with more than 30 years of experience. A leader in oncoplastic techniques and breast cancer quality initiatives, he has served in senior hospital leadership roles and also advises on cancer innovation. He is active in the American Society of Breast Surgeons and dedicates his time to help shape precision cancer care.
Jamie E. McKenzie, MD
Dr. McKenzie is a fellowship-trained hematologist-oncologist who practiced at Tampa General Hospital, with prior training at Massachusetts General Hospital and Dana-Farber Cancer Institute. She is widely known for her multidisciplinary, holistic approach to breast cancer care, particularly for younger women, and brings a medical oncology perspective on how to align systemic therapy decisions with surgical management.
13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy